Introduction
Antiestrogenic drugs such as tamoxifen (Tam) are among the most effective and least toxic systemic therapies currently available for the management of hormone-responsive breast tumors. However, approximately half of all advanced breast cancers respond to hormonal therapy, and almost all responsive tumors eventually relapse due to the development of Tam resistance (Osborne and Fuqua, 1994; Clarke et al., 2001) . Acquired resistance to Tam is a serious therapeutic problem, and major efforts are now being made to understand the underlying mechanisms responsible for this condition (Osborne and Fuqua, 1994; Clarke et al., 2001) . It is unlikely that loss of estrogen receptor (ER), signaling contributes to antiestrogen resistance, as both Tam-resistant tumors and breast cancer cell lines frequently demonstrate sustained ER content and remain responsive to pure antiestrogens and other hormone therapies (Brunner et al., 1993; Encarnacion et al., 1993; Lykkesfeldt et al., 1994) . Numerous mechanisms have been proposed to explain the phenomenon of Tam-resistance in ER-positive breast cancers, including altered drug metabolism (Osborne et al., 1991) , altered binding of co-activators and/or corepressors (Takimoto et al., 1999) , altered signal transduction pathways that modulate ER activity (Kato et al., 1995; Atanaskova et al., 2002) , mutant or loss of ER expression , and AIB1 and HER-2 expression levels are shown to be associated with Tam resistance (Osborne et al., 2003) . It has recently been shown in a preclinical in vivo model that overexpression of HER-2 increases the estrogen agonist activity of Tam leading to tumor growth stimulation . It is now clear that breast cancer development and progression involves complex interactions between steroid hormone and growth factor signaling pathways (Nicholson et al., 1999; Nicholson and Gee, 2000; Atanaskova et al., 2002; Schiff et al., 2004) . Identification of a suitable molecular target in these tumors would facilitate the development of a logical therapeutic approach.
The protein kinase C (PKC) signaling pathway has been implicated in breast cancer in various studies. For example, breast cancer biopsies exhibit higher levels of total PKC activity compared to the surrounding normal tissues (Borner et al., 1987; O'Brian et al., 1989) . Selective regulation of expression of PKC isoforms has also been observed in multiple drug-resistant MCF-7 cells compared to wild-type cells (Lee et al., 1992; Blobe et al., 1993) . PKC represents a family of at least 12 serine/threonine kinases that participate in signal transduction events in response to specific hormonal and growth factor stimuli (Nishizuka, 1992) . Differences in their structure and substrate requirements have permitted division of the isoforms into three groups: (i) conventional PKCs (cPKC) (a, bI, bII and g) require the full complement of negatively charged membrane phospholipids, calcium and diacylglycerol (DAG) or phorbol esters for full activation. (ii) Novel PKCs (nPKC) (d, e, y, and Z) do not require calcium and (iii) atypical PKCs (aPKC) (z and i/l) are both phorbol ester and calcium independent (Newton, 1997; Way et al., 2000) . The classic model for cPKC activation by extracellular signals involves the hydrolysis of membrane phospholipids by phospholipase C (PLC) to generate the second messengers DAG and inositol triphosphate (IP3). The binding of DAG and phosphatidylserine to the regulatory domain of cPKC is followed by binding of Ca 2 þ , the concentration of which has risen in response to IP3. For this activation to occur, PKC must translocate from the cytosol to the membrane, a process controlled by a series of phosphorylation reactions and binding of cofactors (Cartee and Kucera, 2000) . PKC was first highlighted as a target in cancer when it was identified as the target of tumor-promoting phorbol esters (Castagna et al., 1982; Goekjian and Jirousek, 1999) . Activation of PKC by phorbol esters prevents apoptosis in response to growth factor withdrawal, and pharmacologic inhibition of PKC causes apoptosis (Jarvis et al., 1994) . PKC isoforms have wide tissue distribution that mediates intracellular responses to a variety of stimuli including growth factors and hormones that accelerate proliferation in human breast tumor cells (Blobe et al., 1994) . Overexpression of PKCa stimulates MCF-7 breast tumor and C6 glioma cell growth (Baltuch et al., 1995; Way et al., 2000) . The mitogenic influence of PKC-a on the growth of breast cancer and other cancers is inferred clinically by the success of ISIS3521, a therapeutic antisense oligonucleotide to PKC-a, in Phase I and II clinical trials of solid tumors (Nemunaitis et al., 1999; Tolcher et al., 2002; Tortora and Ciardiello, 2003) . In addition, there are data to show that PKC-d is involved in cell migration and apoptosis in various cell types (Newton, 1997; Kruger and Reddy, 2003; McCracken et al., 2003) . The isoform-specific functions of PKC in mammary epithelium are only partially understood, and with a better definition of the role the PKC isoforms play in the promotion of mammary tumor cell growth and antiestrogen resistance more specific therapies could be designed.
To assess the potential role of PKC in antiestrogen resistance, PKC isoform levels were determined in four different antiestrogen-resistant models. We found a significant increase in PKC-a and PKC-d levels in three out of four resistant cell lines. It was previously shown that PKC-a overexpression in MCF-7 and T47D shifts from hormone-dependent to hormone-independent breast cancers (Tonetti et al., 2000) , and therapeutic antisense oligonucleotide PKC-a, are in phase I and II clinical trials (Nemunaitis et al., 1999) . In this study, we determined the role of PKC-d in hormone-mediated signaling, Tam resistance and breast cancer progression. Our data show that overexpressing active PKC-d in Tam-sensitive MCF-7 cells (PKC-d/MCF-7) led to Tam resistance both in vitro and in vivo. Inhibition of PKC-d by rottlerin, a relatively specific inhibitor of PKC-d (Kruger and Reddy, 2003) , or siRNA significantly inhibited E2-and Tam-induced cell proliferation in all the antiestrogen-resistant cells. These data support a role for PKC-d in antiestrogen resistance in ER-positive breast tumor cells, thus providing a new target for further research and treatment approaches.
Results

PKC-d levels are high in antiestrogen-resistant cells
Current endocrine therapies for breast cancer are targeted to inhibit ER-mediated signaling by either depriving the tumor cell of estrogen (aromatase inhibitors) or by blocking estrogen receptor signaling by antiestrogens such as Tam or fulvestrant (ICI) (MacGregor and Jordan, 1998; Johnston et al., 2003) . However, almost all Tam-responsive tumors eventually relapse due to the development of Tam resistance. One of the mechanisms by which cell lines develop resistance to antiestrogens is through the activation of alternate signaling pathways that support cell growth. We have previously shown that PKC-d plays a major role in E2-induced MAPK activation and cell proliferation . We postulated that overexpression of one of the signaling molecules involved in E2-mediated cell proliferation such as PKC-d could lead to growth in the presence of Tam leading to resistance. To test the above concept, we determined the levels of PKC isoforms in four different antiestrogen-resistant models: (i) Tam/MCF-7 cells (cells resistant to Tam, also known as MCF-7/TAM R -1 subline) were generated by selecting the variant against 10 À6 M Tam (Lykkesfeldt and Briand, 1986; Lykkesfeldt et al., 1994) . (ii) ICI/MCF-7 cells (cells resistant to ICI, also known as MCF-7/182 R -6 subline) were generated by selecting the variant against 10 À7 M ICI 182,78 (Lykkesfeldt and Briand, 1986; Lykkesfeldt et al., 1995) . (iii) Forced overexpression of HER-2 by HER-2/MCF-7 cells (also known as MCF-7/ HER2-18) resulted in Tam resistance (Benz et al., 1993; Kurokawa et al., 2000) . (iv) EGFR/MCF-7 cells (forced overexpression of EGFR resulted in Tam resistance) (Kruger and Reddy, 2003; Selina et al., 2004) . Three out of four antiestrogen-resistant cells (Tam/MCF-7, ICI/ MCF-7 and HER-2/MCF-7) exhibited a significant increased in total and activated PKC-d protein levels compared to sensitive cells by Western blot analysis ( Figure 1a ). In addition, PKC-d activity was confirmed by the PKC-d kinase assay (data not shown). However, EGFR/MCF-7 cells showed only a marginal increase in PKC-d levels when compared to control cells. To rule out the possibility that loss of ERa is contributing to antiestrogen resistance in our models, we determined ERa levels in antiestrogen-resistant andsensitive cells by immunoblot analysis. Our data show no significant differences in ERa levels in antiestrogen-resistant cell lines compared to sensitive cells (Figure 1b) .
In order to identify whether other PKC isoforms are elevated in antiestrogen-resistant cells, we screened a panel of PKC isoforms in antiestrogen resistance cell lines. Immunoblot analysis revealed no significant changes in most of the PKC isoforms, except in PKCd and PKC-a in three (Tam/MCF-7, ICI/MCF-7 and HER-2/MCF-7) out of four antiestrogen-resistant cells (Figure 2) . Again, only a marginal increase in PKC-a level is seen in EGFR/MCF-7 cells. Overexpression of PKC-a was shown to play a major role in growth signaling during the shift from the hormone-dependent to hormone-independent stage, and antisense oligonucleotides to PKC-a are in phase I and Phase II clinical trials (Nemunaitis et al., 1999; Tonetti et al., 2000 Tonetti et al., , 2003 . However, very little is known about the role of PKC-d in the regulation of antiestrogen resistance. Therefore, we focused our attention on PKC-d isoform.
PKC-d overexpression reduces Tam-induced growth inhibition in vitro
We have demonstrated that PKC-d is overexpressed in three out of four antiestrogenresistant cells. However, it is not clear whether the increase in PKC-d is responsible for or associated with antiestrogen resistance. In order to determine if PKC-d overexpression leads to antiestrogen resistance, we developed stable cell lines that express HA-tagged activated (40 kDa catalytic fragment) PKC-d cDNA (Soh et al., 1999) in antiestrogen-sensitive MCF-7 cells. After initial identification of clones by HA tag (Figure 3a) we evaluated PKC-d expression by immunoblot analysis, and we identified two clones by immunofluorescence (Figure 3b Figure 2 Comparison of PKC isoforms. Cells were grown and lysates were prepared as shown in Figure 1 . Aliquots of cell extract (50 mg) were separated on SDS-PAGE gel and transferred to a membrane. PKC-a levels were elevated in addition to PKC-d in three out of four antiestrogen-resistant cell lines. Blots were probed with the isozyme-specific antibodies indicated on the left. Equal amount of protein loading was assessed by stripping the membrane and re-probing with G3PDH antibody
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SM Nabha et al role in antiestrogen resistance (Tonetti et al., 2000 (Tonetti et al., , 2003 , therefore we determined PKC-a levels in PKC-d/ MCF-7 clones by Western blot analysis. We have not seen any major changes in PKC-a protein levels in PKCd/MCF-7 clones compared to control cells ( Figure 3c ). PKC-d/MCF-7 (clone 18) and control cells were exposed to a range of 4-OH Tam 
Overexpression of active PKC-d increases phospho-AKT and -MAPK levels
PKCs reside in the cytosol in an inactive conformation and translocate to the membrane (or other subcellular sites) upon activation, where they modify various cellular functions through phosphorylation of target substrates. Treatment of cells with TPA results in the activation of c-Raf and MAPK within minutes, suggesting the involvement of PKC in the signaling pathway leading to MAPK activation (Rapp, 1991; Ueda et al., 1996) . Although these observations suggest a link between PKC and MAPK activation, there has been no direct demonstration that all members of the PKC family actually activate this pathway. In order to determine the major signaling pathways involved in PKC-d-mediated Tam resistance, we determined the levels of phosphorylated AKT and MAPK in resistant cell lines compared to sensitive cells by Western blot analysis. Our data show a significant increase in phospho-AKT levels in all the antiestrogen-resistant cell lines when compared to control cells. However, phospho-MAPK levels are elevated in Tam/MCF-7 and ICI/MCF-7 cell lines, but surprisingly not in EGFR/ MCF-7 and HER-2/MCF-7 cells (Figure 4a ). However, phospho-MAPK levels are significantly enhanced in both EGFR/MCF-7 and HER-2/MCF-7 cell lines in the presence of TGFa (50 ng/ml), suggesting that EGFR/ MCF-7 and HER-2/MCF-7 cells need additional stimulation to induce MAPK activation ( Figure 4b ). In order to determine if PKC-d overexpressing clones (PKC-d/MCF-7 cells) also show increased AKT and MAPK phosphorylation, we did Western blot analysis. PKC-d-overexpressing clones also show increased phospho-AKT and phospho-MAPK levels compared to control cells (Figure 5a ). No significant changes are 
Inhibition of PKC-d decreases phospho-AKT and -MAPK levels and cell proliferation in antiestrogen-resistant cell lines
In order to determine if inhibition of PKC-d blocks AKT and MAPK activation in antiestrogen-resistant cells, we employed rottlerin, which is a selective pharmacologic inhibitor of PKC-d (Gschwendt et al., 1994; Kruger and Reddy, 2003) . Since basal PKC-d levels are elevated in most of the antiestrogen-resistant cell lines, we used Tam/MCF-7 cells as a model to determine the effect of different concentrations of rottlerin (2-5 mM) on PKC-d, MAPK and AKT levels. At rottlerin concentrations of 3-5 mM, the cells exhibited a significant reduction in PKC-d (Figure 6a ), phospho-MAPK and phospho-AKT levels ( Figure 6b ). Cells growing in the presence of rottlerin (3 mM) appear to remain viable, as indicated by their morphological appearance, by lack of floating cells, and by the ability of the cells to exclude trypan blue (>90% viable). However, rottlerin at 5 mM showed significant toxicity after 72 h of treatment. Therefore, most of our experiments were carried out at 3 mM rottlerin concentration. 
MCF-7
Tam/MCF-7 PKC-d levels are high in Tam-resistant tumor compared to Tam-sensitive tumor We have examined whether PKC-d levels increase in MCF-7 tumors that progress from Tam sensitive to resistant using an in vivo xenograft model (Osborne et al., 1991) . Immunoblot analysis of the four tumors from the Tam-sensitive and -resistant tumor groups showed a significant increase in PKC-d levels in Tam 
PKC-d overexpression leads to Tam resistance in vivo
Finally, we tested whether increased expression of activated PKC-d leads to Tam resistance in vivo. We injected the PKC-d/MCF-7 and control MCF-7 cells subcutaneously on either side of an ovariectomized mouse in the presence of b-estradiol (0.72 mg/pellet, 60-day slow release pellets) and/or Tam (5 mg/biodegradable carrier-binder pellet). Animals were scored for tumor formation initially after 10 days and then twice weekly for another 5 weeks. Data indicate that MCF-7 (control) tumor cells when treated with E2 and Tam showed a significant inhibition of tumor growth (8077286, mean7s.e.) (Po0.05) compared to E2 treatment (20207563, mean7s.e.) in vivo. In contrast, PKC-d/MCF-7 tumor cells when treated with E2 and Tam showed a marginal inhibition of tumor growth (25627206, mean7s.e.) compared to E2 treatment (28167458, mean7s.e.) (P>0.05) in vivo (Figure 10 ). These data suggest that overexpression and/or activation of PKC-d may be one of the critical changes involved in antiestrogen resistance.
Discussion
Antiestrogenic drugs such as Tam provide an effective therapy for women with hormone-dependent cancer in the neo-adjuvant, adjuvant and advanced disease settings (Fisher et al., 1996) . However, long-term exposure to Tam can lead to resistance and even to tumor growth stimulation (Horwitz, 1995; Santen, 1996; Berstein et al., 2003) . The signaling pathways by which breast tumors acquire the ability to grow in the presence of antiestrogens such as Tam remain poorly understood. One of the mechanisms by which cell lines develop resistance to antiestrogens is through the utilization of alternative signaling pathways that support cell growth in the presence of antiestrogens. Several different groups including our own have shown that PKC-d plays a major role in E2-mediated signaling (Shanmugam et al., 1999; Keshamouni et al., 2002) . Based on the above data, we postulate that overexpression of PKC-d may be one of the adaptive mechanisms involved in Tam resistance in human breast tumor cells. To explore this possible mechanism, we examined the PKC isoform expression profiles in four different in vitro antiestrogenresistant cell lines. Interestingly, three out of four antiestrogen-resistant cell lines (Tam/MCF-7, ICI/ MCF-7 and HER-2/MCF-7) expressed significantly high levels of both total and activated PKC-d levels compared to sensitive cells (Figure 1a) . EGFR/MCF-7 cells showed only a marginal increase in PKC-d levels when compared to control cells. One of the reasons for 
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SM Nabha et al low PKC-d levels in EGFR/MCF-7 cells may be that E2-induced MAPK activation was previously shown to be predominantly mediated through HER-2/PKC-d/ras signaling (60-70%) and through the EGFR/ras signaling pathway 20-30% . All the antiestrogen-resistant cells express ER alpha (Figure 1b) . These data suggest that the differences in antiestrogen response in these models are not attributable to loss of ER. (Osborne et al., 1987 (Osborne et al., , 1991 . Taken together, these results support our hypothesis that overexpression and/or activation of PKC-d leads to Tam resistance.
Experiments from a number of laboratories now support the idea that PKC-d is a positive regulator of breast cancer growth and metastasis (Kiley et al., 1999a, b; Keshamouni et al., 2002; Kruger and Reddy, 2003; McCracken et al., 2003) . However, there is also literature, largely based on studies with non-mammary cells, suggesting that PKC-d participates in cell death and growth inhibition (Cross et al., 2000; Majumder et al., 2000; Cerda et al., 2001; Blass et al., 2002; DeVries et al., 2002) . In some systems, the apoptotic effect of PKC-d has been associated with a cleavage of the catalytic domain from the regulatory domain (Koriyama et al., 1999; Reyland et al., 1999) . Cleavage of the catalytic domain of PKC-d by caspases has been reported in cells treated with ionizing radiation, tumor necrosis factor alpha and etoposide (Koriyama et al., 1999; Majumder et al., 2000; Blass et al., 2002) . However, a role for PKC-d in promoting mammary tumor growth is supported by other laboratories as well. MDA-MB-231 and MCF-7 cells treated with antisense PKC-d or rottlerin exhibited impaired survival in response to g-radiation (McCracken et al., 2003) . In MTLn3 mammary tumor cells, expression of the inhibitory PKC-d regulatory domain (RDd) inhibited growth in soft agar, cell motility and attachment (Kiley et al., 1999b) . We have previously shown that inhibition of PKC-d with the dominant-negative mutant or by rottlerin lead to the inhibition of estradiol-stimulated MAPK (Erk)-activation in MCF-7 cells . Results from different laboratories as well as our data provide evidence that PKC-d may function as a prosurvival factor in human breast tumor cells.
It was previously shown that the PI3K/AKT pathway has an important role in preventing cells from undergoing apoptosis and contributes to the pathogenesis of cancer. For example, activated AKT phosphorylates specific targets such as Bad, caspase-9, forkhead transcription factors and IKK-a, thereby promoting cell survival (del Peso et al., 1997; Cardone et al., 1998; Brunet et al., 1999; Romashkova and Makarov, 1999) . Furthermore, AKT was shown to be involved in cell proliferation by regulating cyclin-dependent kinase (CDK) inhibitors such as p21 Cip1/WAF1 (Zhou et al., 2001) and/or p27 Kip1 (Liang et al., 2002; Shin et al., 2002; Sekimoto et al., 2004) . The growth-inhibiting activity of p21
Cip1/WAF1 and p27
Kip1 is strongly correlated with its nuclear localization (Goubin and Ducommun, 1995; Sherr and Roberts, 1995) . AKT was shown to phosphorylate a threonine residue (T145) in p21
Cip1/WAF1 and threonine (T157) in p27 Kip1 , leading to the cytoplasmic localization of p21
Kip1
, and enhancing cell proliferation (Zhou et al., 2001; Shin et al., 2002) . Our data show that PKC-d overexpression leads to activation of MAPK and AKT, and inhibition of PKC-d blocks AKT and MAPK activation. These data suggest the possibility that inhibition of PKC-d may enhance apoptosis and reduce cell proliferation in antiestrogen-resistant cells.
Studies from Dr Tonetti group have shown that overexpression of PKC-a, in MCF-7 or T47D cells, leads to in vivo tumor growth in the presence of Tam and in the absence of estrogen stimulation, suggesting a hormone-independent phenotype in vivo (Tonetti et al., 2000; Chisamore et al., 2001) . In addition, they have shown that estrogen inhibits tumor cell growth in PKCa-overexpressing cells both in vitro and in vivo (Chisamore et al., 2001). In contrast, PKC-d-overexpressing MCF-7 cells (PKC-d/MCF-7 cells) grow in the presence of estrogen; however, a combination of estrogen and Tam was unable to significantly inhibit the tumor growth in vivo. However, in control MCF-7 cells, estrogen stimulated tumor growth, and the combination of estrogen and Tam significantly inhibited tumor growth (Figure 10 ). The data indicate the possibility that the molecular mechanism by which PKC-d and PKC-a induces antiestrogen resistance may be different and it needs to be further studied.
Substantial clinical and experimental evidence suggests that increased growth factor signaling, especially of EGFR/HER-2, is associated with reduced response to Tam (Kurokawa et al., 2000; Knowlden et al., 2003; Schiff et al., 2004) . Unfortunately, most of the drugs, especially against the EGFR/HER-2 pathway, have failed to elicit a significant response in many solid tumors including breast cancer (Dancey and Freidlin, 2003 ). An exception is the HER-2 targeting monoclonal antibody herceptin, which shows a significant response in HER-2-overexpressing tumors (McKeage and Perry, 2002) . One of the reasons for the limited success of drugs targeted against EGFR/HER-2 to reverse or prevent the antiestrogen resistance may be the constitutive activation of downstream signaling molecules such as PKC-d, MAPK and AKT that support cell growth in the presence of antiestrogens. Studies from our group and others have shown that activation of MAPK (Benz et al., 1993; Kurokawa et al., 2000) and/or AKT (Campbell et al., 2001; Sun et al., 2001 ) plays a major role in antiestrogen resistance. It is not clear at present whether targeting AKT or MAPK alone or together will be the most efficient method of treatment in Tam-resistant tumor cells. However, our data show that inhibition of PKC-d by rottlerin significantly reduces MAPK and AKT activity and cell proliferation in all the four antiestrogen-resistant cell lines (Figures 6, 7 and 9) . These observations suggest that PKC-d overexpression may be one of the common signaling pathways activated in antiestrogen-resistant cells. These data support a role for PKC-d in antiestrogen resistance in ER-positive breast tumor cells, thus providing a new target for further research and treatment approaches.
Materials and methods
Cell lines and reagents
The human breast carcinoma cell line MCF-7 was obtained from the American Type Culture Collection and maintained in Dulbeco's modified Eagle's medium (DMEM), supplemented with 5% FCS and insulin and antibiotics penicillin and streptomycin (Life Technologies, Gaithersburg, MD, USA). MCF-7 cells that have been stably transfected with full-length HER2 cDNA (MCF-7/HER2-18) or control vector (MCF-7/ neo) have been described previously (Benz et al., 1993) . Tam/ MCF-7 also known as MCF-7/Tam R -1 cells (these cells grow in the presence of 4-OH Tam (10 À6 M) (Lykkesfeldt and Briand, 1986) and ICI/MCF-7 (Lykkesfeldt et al., 1995) (these cells grow in the presence of ICI 182,780) were generously provided by Dr A Lykkesfeldt (Danish Cancer Society, Copenhagen, Denmark) and have been described previously (Lykkesfeldt and Briand, 1986; Lykkesfeldt et al., 1994 Lykkesfeldt et al., , 1995 . 17b-Estradiol (E2), 4-OH Tam and TPA were purchased from Sigma Chemical Co. (St Louis, MO, USA). ICI 182,780 was purchased from Tocris (Ballwin, MO, USA); phospho-PKC-d rabbit polyclonal, phospho-Akt (Ser 473) rabbit polyclonal from Cell Signaling Technology (Beverly, MA, USA); PKC-d (monoclonal), PKC-a, PKC-b and PKC-e, etc. from Transduction Laboratories (BD Biosciences, San Diego, CA, USA); phospho-MAPK antibody from New England Biolabs, (Beverly, MA, USA). Rottlerin was purchased from Calbiochem (San Diego, CA, USA), ER alpha antibody from NeoMarkers (Freemont, CA, USA). Anti-glyceraldehyde-3-phosphate dehydrogenase (G3PDH) rabbit polyclonal was obtained from Trevigen (Gaithersburg, MD, USA). An anti-HA antibody (clone Y-11), Donkey anti-mouse IgG-FITC was purchased from Santa Cruz Biotechnology, Inc., (Santa Cruz, CA, USA).
Isolation of stable transfectants
MCF-7 cells were stably transfected with full-length EGFR cDNA (pRCMV3 vector obtained from Dr GN Gill, University of California, San Diego, CA, USA) (Davis, 1993) or with HA-tagged activated PKC-d cDNA (Dr IB Weinstein, Columbia University, NY, USA) (Soh et al., 1999) by electroporation using a Biorad gene pulsar at 950 mF and 0.22 kV/cm (t ¼ 12-14 ms). Stable transfectants were selected in the presence of 250 mg/ml G418 (Life Technologies, Gaithersburg, MD, USA) after 2-3 weeks. Individual antibioticresistant colonies were isolated and screened for the expression of the corresponding protein by Western analysis using anti-EGFR antibody (clone-528) or anti-HA antibody (clone Y-11). All cell lines were routinely tested for mycoplasma contamination and found to be negative.
Western immunoblot analysis
When cells reach 60-70% confluence, the regular medium was removed and cells were grown for another 48 h in phenol redfree DMEM containing 5% charcoal stripped fetal bovine serum (FBS). Cells were lysed and Western blotting was performed as described previously (Reddy et al., 1999 ) using a standard protocol. In brief, crude protein extracts were obtained by lysing 5 Â 10 6 cells in a buffer (50 mM Tris-HCl (pH 7.6), 1% NP-40, 2 mM EDTA, 0.5% Na deoxycholate, 150 mM NaCl, 1 mM Na ortho-vanadate, 2 mM EGTA, 4 mM Na p-nitro phenyl phosphate, 100 mM Na fluoride) supplemented with protease inhibitors (leupeptin (0.5%), aprotinin (0.5%) and PMSF (0.02%)). Samples containing 50 mg of total protein were electrophoresed on 7.5% or 10% SDS-polyacrylamide gels and transferred onto nitrocellulose membrane by electroblotting. Membranes were probed with antibodies as indicated, followed by HRP-conjugated mouse or rabbit secondary antibodies (Amersham) and enhanced chemiluminescence detection (Amersham). For quantification, band intensities of the PKC-d, AKT and MAPK were quantified using Biorad's 'Quantity one' software and normalized to the corresponding total GD3pH levels.
RNA interference assay
Cells were plated in 24-well tissue culture plates (Corning Laboratories, Houstan, TX, USA), at a density of 1 Â 10 4 cells/ well, in DMEM containing 5% FBS. After 24 h, the seeding medium was removed, cells were washed twice with PBS, and the medium was replaced with phenol red-free DMEM with 5% charcoal-stripped serum. To suppress PKC-d expression, cells were transfected with 0.8 mg/well of pKD-PKCd-v3 (mammalian PKC-d siRNA expression plasmid from Upstate, Lake Placid, NY, USA) using Lipofectamine transfection reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Cells were harvested and extracts prepared for Western blot analysis at 72 and 96-h time points after transfection.
Monolayer growth assay
Cells were plated in six-well tissue culture plates (Corning Laboratories, Houstan, TX, USA), at a density of 1 Â 10 4 cells/ well, in DMEM containing 5% FBS. After 24 h, the seeding medium was removed, cells were washed twice with PBS, and the medium was replaced with phenol red-free DMEM with 5% charcoal-stripped serum, with or without drugs. The medium was replaced with fresh medium, containing the same supplements, on day 3. The cells were counted in triplicate after being suspended in PBS with 1 mM EDTA, on day 5.
DNA synthesis
Cells were plated in 24-well tissue culture dishes (Corning) at a density of 1 Â 10 5 cells/well in DMEM with 5% FBS. After 24 h, the seeding medium was removed, the cells were washed 2 Â with PBS, and the cells were incubated in 0.1% BSA and phenol red-free DMEM (1 ml/well). After 24 h medium was supplemented with or without drugs. After 16 h, 0.25 mCi [ 3 H]thymidine (82.3 Ci/mmol, NEN products, Boston, MA, USA) in a volume of 25 ml was added to each well for a 1 h pulse. Cells were harvested and the rate of DNA synthesis was estimated in triplicate by measuring the acid-perceptible radioactivity as described previously (Reddy et al., 1992) . Radioactivity was quantified in a Beckmann LS 7000 liquid scintillation counter with an efficiency of 64%.
Confocal immunofluorescence microscopy
For immunofluorescence labeling, cells were grown at low density on sterilized eight well permanox slides from LAB-TEK (Nalge Nunc International, Naperville, IL, USA) in DMEM phenol red free medium with 5% charcoal stripped serum for 48 h. After washing with PBS, the cells were fixed in ice-cold methanol for 5 min. Nonspecific blocking was done in 5% BSA in PBS solution for 30 min, followed by incubation with PKC-delta Ab (1 : 50 dilution) in Tris buffer saline (50 mM Tris-HCl (pH 7.4), 150 mM NaCl) overnight at 41C. Cells were washed 4 Â 5 min with PBS containing 0.05% Tween 20 and then incubated with donkey anti-mouse IgG-FITC for 1 h in the dark (1 : 100 dilution). Cells were washed 3 Â with PBS containing 0.05% Tween 20. Cells were incubated with Slow Fade reagent (Molecular Probes, OR, USA) and the glass coverslip was mounted on the slides. Immunostaining was observed under a Leica confocal microscope, and representative photographs were captured using SPOT RT software v3.0.
Xenograft model studies in mice
The antiestrogen-resistant xenograft model was previously described (Osborne et al., 1991) . In brief, female athymic mice, 4-5 weeks of age, were supplemented with a 0.25 mg, 21-day release, 17 b-estradiol pellet in the dorsal space and then injected with MCF-7 cells s.c. just under and behind the forelimb. Once tumors reached an approximate volume of B200 mm 3 , the estrogen pellet was removed and mice were treated with Tam. Some tumors were harvested after 3-4 Abbreviations ER, estrogen receptor; EGFR, epidermal growth factor receptor; MAPK, mitogen-activated kinase; PKC, protein kinase C; Tam, 4-OH-tamoxifen.
